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Background: Serial measurement of NT-proBNP is performed routinely in the monitoring and assessment of
the effectiveness of therapy in patients being treated for chronic heart failure (CHF). Intra-individual changes
in NT-proBNP levels over time are compared typically to a reference change value (RCV) determined using
either a standard [i.e., nested analysis of variance (nANOVA)] or a lognormal approach. The RCV deﬁnes
the minimum percent change in serial analyte values that exceeds the percent change expected due to bio-
logical variation alone. Currently, there is no consensus on which approach (nANOVA or lognormal) to deter-
mining RCV is better.
Aims: Based on these considerations, we aimed to illustrate the impact of data transformation on the calcu-
lation of the biological variation of NT-proBNP and discuss the utility of logarithmic transformation in mon-
itoring patients with heart failure.
Methods: 15 healthy subjects were enrolled after informed consent; 5 blood specimens were collected twice a
week. Nested ANOVA from replicate analyses was applied to obtain components of biological variation, on
the raw data and after data transformation.
Results: NT-proBNP distribution being highly skewed required data transformation. Natural log transforma-
tion yielded normalization. An example demonstrates that for untransformed values the RCV was overesti-
mated for low concentrations of NT-proBNP and underestimated for higher concentrations.
Conclusions: Log-transformed data are often used in the establishment of reference intervals for evaluating
laboratory tests results in clinical practice, especially when the reference interval data are not Gaussian dis-
tributed. As log-normal approach is the best approach to determining RCV values we encourage its use asses-
sing the clinical utility of NT-proBNP serial testing. We propose that the log-normal approach becomes the
standard approach to determining RCV and replaces the use of nANOVA.© 2011 Elsevier B.V. All rights reserved.1. Background
Several clinical trials have demonstrated that modiﬁcations
throughout a follow-up greater than 30% of BNP/NT-proBNP concen-
trations have a relevant prognostic value [1–4]. The large biological
variability of B-type natriuretic peptides, may limit their usefulness
in serial measurements in individual patients, and one study reports
that only large reductions of concentration of natriuretic peptides
are associated with improved outcome in New York Heart Association
class III–IV outpatients [5]. However, despite the large biological, Chirurgia e Odontoiatria, via
ilano, Milano, Italy. Tel. +39
ssi).
rights reserved.variation of these biomarkers, early studies showed that N-BNP-
guided treatment of heart failure reduced total cardiovascular events,
and delayed time to ﬁrst event compared with intensive clinically
guided treatment [6]. Furthermore, several meta-analyses showed
better outcomes of the biomarkers-guided therapy in chronic heart
failure in respect to the standard clinical approaches [7,8], especially
in patients younger than 75 years [9,10]. Indeed, the results of a pro-
spective randomized study, recently published, showed that com-
pared to multidisciplinary care alone, the addition of NT-proBNP-
guided intensive patient management improves clinical outcome in
patients following hospitalization due to heart failure.
Intra-individual changes in NT-proBNP levels over time are com-
pared typically to a reference change value [RCV; formerly, critical
difference (CD)] determined using either a standard [i.e., nested anal-
ysis of variance (nANOVA)] or a lognormal approach. The RCV deﬁnes
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percent change expected due to biological variation alone [11,12].
Currently, there is no consensus on which approach (nANOVA or log-
normal) to determining RCV is better. Data on biological variation of
NT-proBNP have been published with markedly differing results
(reviewed in [13]), mainly related to the use of data transformation,
particularly in patients with chronic heart failure [14,15]. As compo-
nent of variation is computed based on nANOVA, the distributional
assumptions underlying the use of this method should be satisﬁed,
which is not the case for skewed distributions, as NT-proBNP's. This
aspect has been underlined in the literature not only for NTproBNP,
but also for other biomarkers in oncologic research [16,17]. Particu-
larly, Fokkema et al. [18] showed that the deviation of the mean
from the median of week to week measurements was much larger
(by a factor of 20) before log-transformation of NT-proBNP concen-
trations. Moreover they underlined that leaving untransformed data
could yield implausible 0 or negative values for downward changes
of the metabolite if the RCV was 100% or more. Also, in the lognormal
case RCVs are nonsymmetric, with clinical implications when asses-
sing downward and upward changes, and obtaining 0 or negative
concentrations is not possible any more.
2. Methods
The design of the study and the analytical procedures were
described in details elsewhere.
Brieﬂy, ﬁve blood specimens were collected from each of 16 ap-
parently healthy laboratory workers (5 M, 11 F) twice a week (Tues-
days and Fridays) over a 17-day period. Blood was collected under
standardized conditions to minimize sources of preanalytic variation.
Sera were separated and stored at −70 °C until analysis.
Nested analysis of variance from replicate analyses was applied to
obtain components of biological variation [11,12]: the mean analyti-
cal variation (CVA), the intraindividual variation (CVI), the interindi-
vidual variation (CVG), and the index of individuality (CVI/CVG) for
assessing utility of conventional population based reference intervals.
Conventionally, if the index of individuality is b0.6 population-based
reference values are of limited value for detecting unusual results
for a particular individual; the opposite applies if >1.4. The RCV, the
minimal signiﬁcant difference (pb0.05) for 2 consecutive measure-
ments and, ﬁnally, the number of specimen required to estimate the
homeostatic setpoint of an individual (with ±10%, with a conﬁdence
of 95%) were calculated. Also approximated values for the compo-
nents of variation for the analyte in its original scale were computed
from the standard deviation of its ln-transformed value (which is
itself a CV). It is to underline that this approximation (based on Tche-
bycheff inequality) holds for small values of CV, say between 30 and
40%. Finally the calculation of the up and down RCVs in the lognormal
approach was computed according to Fokkema [18].
Distributional assumptions for applying F test were assessed
graphically by histograms and rankit plots [19], and by the Shapiro–
Wilk test on the observations as a whole and for each individual. A
modiﬁed D'Agostino test for skewness was also performed [20] to
determine the source of non-normality. Homogeneity of variances
between subjects was assessed by means of Barlett test.
Stata 11 (StataCorp, College Station, TX, USA) was used for
computation.
3. Results
Normality assumptionwas violated for the whole data both graph-
ically (Fig. 1) and at signiﬁcance test (pb0.001) with marked right
skewness (pb0.001). The assumption was questionable in half of
the individuals graphically and in 5 at signiﬁcance test (pb0.015).
Moreover, variance dishomogeneity was present (pb0.001). There-
fore normalizing transformations were advisable before assessingbiological variability. A series of usual transformations was used: nat-
ural logarithmic, Box–Cox with zero skewness, inverse and square
root (Table 1). Natural logarithm (ln) and Box–Cox functions only pro-
duced normality (Fig. 1). The analytical, intraindividual and inter-
individual components of variation were all lower in the case of
normalizing transformations. The index of individuality was close to
0.6 for transformed variables only. Two consecutive measures must
change by 16 to 34% before signiﬁcance can be claimed when a nor-
malizing transformation is applied, and by 62 to 159% for the raw data.
Finally the number of specimen to be collected to estimate the
homeostatic set point of an individual was comparably lower in the
case of normalizing transformations.
The consequences of using or not a normalizing transformation
are illustrated in the numerical example of Table 2. We report hypo-
thetical values of two consecutive measures. The ﬁrst measurement
ranges from 10 to 500. The follow-up measurement was calculated
so to be signiﬁcantly different from the ﬁrst one, based on the RCV
of 160% (from the standard approach) and 26% (from the lognormal
approach). Concentrations are reported for both an upward (up)
and a downward (down) change of the metabolite. In the lognormal
approach, these changes are nonsymmetric; for illustration, up and
down concentrations according to the mean RCV are also reported.
As shown in the table, changes computed with the standard approach
are larger than those computed with the lognormal approach for low
concentrations of NT-proBNP and lower for high concentrations of
NT-proBNP. Moreover, the down RCV yields unplausible negative
concentrations.
4. Discussion
These results show that the biological variation and the RCV are
greatly affected by the distribution of the original data. Ignoring the
data distribution results in distorted estimates, with overestimation
of the RCV for lower concentrations and underestimation for higher
concentration of the metabolite.
A review by Clerico [21] discusses on how the RCV reported in the
literature (calculated on untransformed values) might be excessive in
regard to the clinical relevance for monitoring changes over time.
Similar considerations are presented by Fokkema [18] who suggest
to adopt a 80% “insurance level” against false positives when comput-
ing RCVs, in replacement of the traditional 95% level. Larger values
will hamper the potential clinical usefulness of the marker, while
low indices of individuality are important in a monitoring situation
were small changes from the set point of the individual need to be
detected in serial measurements. Similarly, the usefulness for moni-
toring will increase for smaller critical differences. The transformed
variables achieved these two goals in our study. As shown by the nu-
merical example, ignoring the skewed distribution of the data results
in higher uncertainty when judging the relevance of the difference
between 2 consecutive measurements.
Our results for the index of individuality on untransformed data
are in keeping with Wu and Smith [22] who report an index of indi-
viduality of 0.92; however, RCV in our series is much higher than
the reported 92%. Conversely, normalizing transformations yield
much smaller estimates on the transformed scale (for ln transforma-
tion: 0.64 and +30 and −23% for the index of individuality and the
up and down RCV, respectively). These ﬁndings support the previous
work of Fokkema [18] who reported up and down RCVs of 29 and
−22%, while the mean RCV of 26% found here is comparable to that
obtained by Bruins [14] in a modiﬁed standard approach, based on
median values of CVT and CVI to overcome the skewness of data.
The values of these indexes are of particular relevance for concluding
on the diagnostic or prognostic ability of NT-proBNP and on its use for
patient monitoring over time, as underlying also by O'Hanlon [23] in a
different population of stable heart failure patients. These results may
be extended to other settings, where the lognormal approach was
Fig. 1. Graphical assessment of the departure from normality. Panels 1 and 3 report the distribution of NT-proBNP (ng/L) and of ln(NT-proBNP), respectively, over all observations
(146 measures in 15 subjects). Panels 2 and 4 show the corresponding rankit plots, including 95% conﬁdence intervals. Both the histogram and the rankit plot illustrate the presence
of skewness of the untransformed NT-proBNP and its disappearance after ln transformation.
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biological variation. This was shown by Tuxen et al. [16] for cancer
antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue
polypeptide antigen (TPA) in the monitoring of ovarian cancer
patients or by van Eyben et al. [17] for serum lactate dehydrogenase
isoenzyme1 (S-LD-1) in the monitoring of patients with testicular
germ cell tumors.
5. Limits of the study
Physicians are used to express results of laboratory tests using
conventional or SI units and rely on biological variability computed
on this scale and log-transformation might appear counter-intuitive.
However, when assessing biological variation this practice may be
potentially misleading if data are not Gaussian distributed. The
RCV will generally be overestimated for lower concentrations of theTable 1
Estimates of biological variation for original and transformed data.
Transformation Normalizing Mean (SD) Min–max CVA% CVI% CVG%
Original scalea – 70.99 (58.5) 13.5–356.0 5.8 57.2 61.1
Lognb Yes 4.02 (0.67) 2.60–5.87 2.7 9.1 14.2
Box–Cox with
zero skewnessd
Yes 2.64 (0.27) 1.98–3.29 2.0 5.4 8.8
Inversee No 0.02 (0.01) 0.00–0.07 24.5 36.4 56.9
Square rootf No 7.92 (2.90) 3.67–18.87 3.6 22.3 29.7
Notes to Table 1.
a Approximated values (based on Tchebycheff inequality) for CVA=10.9, CVI=36.6, CVG
b ln(NTproBNP).
c RCV mean, RCV for downward change and RCV upward change are reported.
d (NTproBNP(−0.22–1))/−0.22.
e 1/NTproBNP.
f NTproBNP0.5.metabolite and underestimated for higher concentrations, as in
the NT-proBNP case shown here (but also for any metabolite with
nonsymmetric distribution) and misinterpretation of the clinical rel-
evance of changes in NT-proBNP in patients with chronic heart failure
or other cardiologic conditions might ensue. The lognormal approach
will provide estimates of the RCV more consistent with the distribu-
tion of the data, and thus we encourage its use. In addition, the
back-transformation to the original scale will allow for nonsymmetri-
cal values of the up/down RCVs, with larger changes needed to claim
clinical relevance for an increase in NT-proBNP and lower changes for
a decrease. Nonsymmetrical values will also prevent the calculation of
implausible (negative) values.
Assessing the RCV is not sufﬁcient for claiming clinical relevance.
The RCV deﬁnes the minimum percent change in serial analyte values
that exceeds the percent change expected due to biological variation
alone. Clinician, when making decision regarding clinical signiﬁcanceIndex of
individuality
Desired analytical
imprecision
Reference change
value (RCV)%
Number of specimens for
homeostatic point ±10%
0.94 28.6 159.38 127.18
0.64 4.6 26.33 (−23; +30)c 3.47
0.62 2.7 16.05 1.29
0.64 18.2 121.53 73.95
0.65 11.2 62.59 19.61
=57.1, Index of Individuality=0.64 and critical difference=105.58.
Table 2
Numerical example to illustrate the minimal change in NT-proBNP needed to claim that the difference is above the value expected due to biological variation alone. Hypothetical
measured baseline values for NT-proBNP are reported in column 2; the value to be reached to claim a difference above the expected one, based on biological variation is reported in
the next columns: Column 3 makes use of the standard approach for computing RCV (untransformed data). Column 4 makes use of the lognormal approach, ignoring the asym-
metric boundaries. Columns 5 and 6 make use of the lognormal approach and apply the asymmetric boundaries for down and up changes in NT-proBNP.
Baseline measure Standard approach Lognormal approach Lognormal approach Lognormal approach
[1] [2] [3] [4] [5] [6]
Patient no. NT-proBNP, ng/l NT-proBNP, ng/l
[up and down: RCV ±160%]
NT-proBNP, ng/l [up and down:
mean RCV ±26%]
NT-proBNP, ng/l [down:
RCV −23%]
NT-proBNP, ng/l
[up: RCV +30%]
1 10 −6 and 26 5 and 18 6 20
2 25 −15 and 65 11 and 58 12 66
3 50 −30 and 130 18 and 138 20 162
4 75 −45 and 195 24 and 240 28 274
5 100 −60 and 260 30 and 331 35 398
6 150 −90 and 390 41 and 552 47 674
7 500 −300 and 1300 99 and 2516 120 3226
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greater than what expected on not only the basis of the biological var-
iation but also a variety of other patient-speciﬁc factors.
Moreover, we used the mean of the within subject biological var-
iation in apparently healthy people to calculate RCV but this approach
has a theoretical disadvantage. In fact in certain pathologies CVI is
higher than in healthy states for certain analytes. In consequence,
the real RCV in these patients would be higher than in the healthy.
However, a compilation of known data on CVI in diseases [24] and
comparison with relevant data in the healthy suggests that, in gener-
al, CVI are indeed similar in health and chronic stable disease. In con-
clusion, for most quantities, data on health can be used appropriately
in monitoring of disease [25].
6. Conclusions
Based on the observed results along with similar ﬁndings reported
in the literature, we suggest that the lognormal approach become the
standard for determining RCV and replace the use of nested ANOVA
on untransformed data, when distributions are nonsymmetric, as is
the case for NT-proBNP. This choice has clinical implications when
assessing the clinical relevance of a change in the metabolite against
its background biological variation.
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